`l_UCENTIS'
`RAN lS ! ZL.JMAS
`Business Use Only
`
`Lucentis PFS (RFB002)
`
`TRD SubTeam meeting
`
`Meeting Date: July 23, 2012
`Meeting Notes Date: August 2, 2012
`Author: - -
`Room: WSJ-340.3.09
`Dial-in information:
`
`J;L.
`
`T eleoorterences. m;g
`
`Team Members: (✓ = Present, * = part-time)
`I Name
`
`Team Members : (✓ = Present,*= part-time)
`
`Executive Summary
`
`--•
`
`
`
`I
`I
`
`I
`
`Lucentis CMC Subteam Meeting Minutes . Meeting Date : July 23. 2012
`
`1 of 6
`
`CONTAINS CONFIDENTIAL BUSINESS INFORMATION, SUBJECT TO PROTECTIVE ORDER
`Novartis Exhibit 2081.001
`Regeneron v. Novartis, IPR2021-00816
`
`
`
`Draft Minutes
`
`Pre-read
`
`Lucentis CMC Subteam Meeting Minutes. Meeting Date: July 23. 2012
`
`2 of 6
`
`CONTAINS CONFIDENTIAL BUSINESS INFORMATION, SUBJECT TO PROTECTIVE ORDER
`Novartis Exhibit 2081.002
`Regeneron v. Novartis, IPR2021-00816
`
`
`
`I
`
`I
`
`- I
`
`
`
`Lucentis CMC Subteam Meeting Minutes. Meeting Date : July 23. 2012
`
`3 of 6
`
`CONTAINS CONFIDENTIAL BUSI NESS INFORMATION, SUBJECT TO PROTECTIVE ORDER
`Novartis Exhibit 2081.003
`Regeneron v. Novartis, IPR2021-00816
`
`
`
`I
`I
`I
`
`• I•
`
`I
`I
`I
`
`I
`
`---
`
`---
`
`-
`
`Lucentis CMC Subteam Meeting Minutes. Meeting Date: July 23. 2012
`
`4 of 6
`
`CONTAINS CONFIDENTIAL BUSI NESS INFORMATION, SUBJECT TO PROTECTIVE ORDER
`Novartis Exhibit 2081.004
`Regeneron v. Novartis, IPR2021-00816
`
`
`
`---.-·-
`
`Lucentis CMC Subteam Meeting Minutes. Meeting Date : July 23. 2012
`
`5 of 6
`
`CONTAINS CONFIDENTIAL BUSI NESS INFORMATION, SUBJECT TO PROTECTIVE ORDER
`Novartis Exhibit 2081.005
`Regeneron v. Novartis, IPR2021-00816
`
`
`
`Action Plan
`
`Code
`
`-
`
`LF
`
`Code
`
`LF
`
`Lucentis CMC Subteam Meeting Minutes. Meeting Date: July 23. 2012
`
`6 of 6
`
`CONTAINS CONFIDENTIAL BUSINESS INFORMATION, SUBJECT TO PROTECTIVE ORDER
`Novartis Exhibit 2081.006
`Regeneron v. Novartis, IPR2021-00816
`
`